Research and experimental development services (примерный перевод: Научно-исследовательские и опытно-услуги) (Турция - Тендер #6371918) | ||
| ||
Для перевода текста тендера на нужный язык воспользуйтесь приложением: | ||
Страна: Турция (другие тендеры и закупки Турция) Организатор тендера: Türkiye Cumhuriyeti Sağlık Bakanlığı Номер конкурса: 6371918 Дата публикации: 20-01-2020 Источник тендера: Единая система закупок Европейского союза TED |
||
Turkey-Ankara: Research and experimental development services
2020/S 013-027220
Prior information notice
This notice is for prior information only
Services
Section I: Contracting authority
Internet address(es):
Main address:
Address of the buyer profile:
Internet address(es):
Main address:
Address of the buyer profile:
Internet address(es):
Main address:
Address of the buyer profile:
Internet address(es):
Main address:
Address of the buyer profile:
Internet address(es):
Main address:
Address of the buyer profile:
Turkish
Internet address(es):
Main address:
Section II: Object
Pre-commercial Procurement of Innovative ICT-enabled Monitoring to Improve Health Status and Optimise Hypertension Care
This PIN announces an open market consultation and provides information about a planned pre-commercial procurement (PCP) carried out by the HSMonitor project, addressing the rising incidence of hypertension and the need for more effective management by empowering patients and the healthcare professionals involved in their care. HSMonitor is looking to procure R&D services in the form of a solution that will provide innovative ICT-enabled monitoring to improve health status and optimise hypertension care. The procurement should address the procurers" unmet needs relating to different aspects (building blocks) of hypertension care: early detection and prevention, healthier lifestyle and nutrition, optimised drug therapy and improving treatment adherence, use of devices and remote monitoring, personalised decision support, interoperability and integration, quality and outcome reporting, patient-professional collaboration and coordination, training and education.
Testing is expected to take place in Istanbul (Turkey); Naples (Italy); Jämtland Härjedalen (Sweden); Zagreb (Croatia); Milan (Italy).
The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions. Each selected operator will be awarded a framework agreement that covers three R&D phases. The 3 phases are: solution design, prototype development, original development and validation and testing of a limited volume of first products or services. After each phase, intermediate evaluations will be carried out to select the best of the competing solutions. The contractors with the best value-for-money solutions will be offered a specific contract for the next phase.
The procurement is expected to start in January 2021 and end in March 2023.
The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions.
Note: the estimated total value listed in Section II.1.5) includes VAT.
This procurement receives funding from the European Union’s Horizon 2020 Research and Innovation Programme, under grant agreement No 856698 — HSMonitor (
). The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.This PIN invites all interested operators to take part in an open market consultation (OMC) which will take the form of a series of meetings: 5 on the premises of each procurer in the period 15.3.2020 — 15.5.2020 (held in local language), and one online meeting. All meetings will be announced on the website:
. The online OMC will be held in English.Section IV: Procedure
Section VI: Complementary information
The PCP procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them (because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs). This PIN is published to announce an open market consultation on a future procurement procedure. The PIN is not a commitment to procure.